Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neuroblastoma 5Prostatic Neoplasms 3Skin Neoplasms 2Precancerous Conditions 2Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Stomach Neoplasms 1Sarcoma, Ewing 1Osteosarcoma 1Non-melanoma Skin Cancer 1Neoplasms 1Medulloblastoma 1Keratosis, Actinic 1Gastritis, Atrophic 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Basal Cell 1Adenomatous Polyps 1Adenomatous Polyposis Coli 1

Interventions

Bevacizumab 234Fluorouracil 220Oxaliplatin 216Irinotecan 215Leucovorin 199Capecitabine 153Cetuximab 146Panitumumab 70Folfox protocol 51regorafenib 43Radiotherapy 38pembrolizumab 37IFL protocol 36HMPL-013 36trifluridine tipiracil drug combination 32Nivolumab 32Drug Therapy 26Neoadjuvant Therapy 24Trifluridine 18Celecoxib 18tislelizumab 17XELOX 17sintilimab 16Trastuzumab 16durvalumab 15atezolizumab 15aflibercept 15Chemotherapy, Adjuvant 15Biopsy 15apatinib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Colorectal Neoplasms × Eflornithine × Clear all
NCT00033371 2020-09-29

Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis

National Cancer Institute (NCI)

Phase 2 Completed
205 enrolled 16 charts
Gastrointestinal

Adenomatous Polyposis Coli, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡